ArticleInternational ophthalmology2025
A case-control prospective study to unravel zinc alpha 2 glycoprotein role in the pathophysiology of diabetic retinopathy.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDiabetic retinopathy (DR) is a leading neurovascular complication affecting the working age group worldwide. Zinc alpha-2-glycoprotein (ZAG) is indeed an important adipokine, and it has been found to play a role in various metabolic conditions, including diabetes, metabolic syndrome and responses to lifestyle changes. In this study, we have assessed the levels of ZAG in the aqueous and vitreous humour of DR cases as a marker for the disease. It's a case-control prospective study wherein 65 Proliferative Diabetic Retinopathy (PDR) patients in the age group of 50-60 years with type 2 diabetes mellitus and with no other ocular complications were included. The PDR cases were classified with Tractional Retinal Detachment (TRD) and Fibrovascular Proliferation (FVP). 15 Macular hole (MH) patients in the age group of 60-70 years with no history of diabetes were included as disease control subjects. The groups were evaluated for demographic variables, biochemical parameters, vitreous ZAG levels and biomarkers. Data between the groups were compared statistically.
resultsA significant increase in ZAG protein levels was observed in both vitreous humour and aqueous humour of PDR cases compared to MH control. A positive correlation was observed between ZAG and various biomarkers like adiponectin, leptin, galectin-3, Vascular endothelial growth factor (VEGF), pentraxin-3 (PTX3) and tumour necrosis factor-alpha (TNF- alpha). Unconditional logistic regression analysis was conducted, and ZAG had 20.167 odds ratio (95% CI 3.927-103.576, P = 0.001).
conclusionThe present study shows that ZAG is increased in the vitreous and aqueous humour of the PDR cases compared to the macular hole. It was also correlated with the already reported biomarkers. It could be a risk factor for the disease based on the odds ratio.
Indexed as
Identifiers
40119982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.